|Bid||300.00 x 800|
|Ask||407.93 x 800|
|Day's range||307.35 - 330.77|
|52-week range||249.48 - 460.21|
|Beta (5Y monthly)||1.17|
|PE ratio (TTM)||42.75|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Charles River (CRL) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Investors are optimistic about Charles River (CRL) on acquisitions of Cognate BioServices and Vigene Biosciences.
How far off is Charles River Laboratories International, Inc. ( NYSE:CRL ) from its intrinsic value? Using the most...